Oral-lyn, an insulin spray by Generex Biotechnology Corporation, acts faster than conventional insulin delivery.
Generex Oral-lyn has a faster onset of action and shorter duration of action than insulin delivered subcutaneously, according to a study published in the journal Diabetes, Obesity and Metabolism.
An independent review of clinical trials of Generex Oral-lyn(TM) shows that the oral insulin spray has a faster onset of action and shorter duration of action than insulin delivered subcutaneously, according to Generex Biotechnology Corporation.
Generex Oral-lyn delivers insulin through the inner lining of the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn does not have pulmonary side effects.
Generex Oral-lyn is safely and efficiently delivered in pain-free, standardized doses via the company’s proprietary RapidMist device, which looks like a simple asthma inhaler, but provides complete absorption through the buccal mucosa (lining of the mouth) with no deposit in the lungs.
“The ease of use of the insulin spray formulation may increase patient acceptance and treatment compliance, thereby potentially reducing complications and improving quality of life for patients with insulin-dependent diabetes,” the review authors wrote.
International Diabetes Federation guidelines identify glycemic control as a crucial factor in management of the disease, yet ensuring insulin therapy compliance can be problematic when up to one-quarter of people with diabetes have needle anxiety.
70,000 children under the age of 15 develop Type 1 diabetes each year, a rate of almost 200 children each day, it is estimated.
The clinical trials of Generex Oral-lyn include patients with Type 1 and Type 2 diabetes.
Incidence of Type 1 diabetes is growing by 3 percent per year in children and adolescents, and at an alarming 5 percent per year among pre-school children.
Currently, an estimated 440,000 children globally live with Type 1 diabetes. Type 2 diabetes was once seen as a disease of adults, but is also growing at alarming rates in children and adolescents.
Recently, Danish firm Novo Nordisk A/S has begun first in man studies for its experimental insulin pill which pill replace the routine injection for diabetics even as India’s Biocon is completing its version of oral insulin for scheduled launch in next 18 months.
NN1952 has been designed to address some of the key challenges relating to oral insulin delivery. Furthermore, it utilises the GIPET (Gastrointestinal Permeation Enhancement Technology) formulation technology from Merrion Pharmaceuticals to facilitate insulin absorption from the gut.
Meanwhile, India’s leading biotherapeutics firm Biocon Ltd’s oral insulin pill is currently undergoing late phase human studies.
Biocon plans to begin commercial production within 18 months, stated Biocon’s managing director Kiran Mazumdar- Shaw, in an interview given to a leading newswire.
Insulin pill, IN-105, in which is in the final phase 3 stage of patient studies.
Insulin pill IN-105, if comes out successful in patient studies, will have huge potential with a certainty to become a multibillion dollar blockbuster.
Oral lyn is being marketed in some parts of the world including India by Shreya Life Sciences Pvt. Ltd, Mumbai.
Global insulin market is expected to grow 15 percent annually through 2010, predicts New York-based MarketResearch.com.
Nearly 246 million people are suffering from diabetes worldwide, according to the International Diabetes Federation. India has the highest number of diabetes patients in the world- nearly 41 million sufferers, followed by China and the U.S.